List view / Grid view
22 August 2025 | By US Pharmacopeia
Join our live webinar with USP as they explore new approaches for impurity profiling - unveiling new frameworks, analytical tools, and regulatory insights that are reshaping pharmaceutical quality standards.
The deal between the two European CDMOs expands Ofichem’s Nordic biotech footprint and drug substance capabilities.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
27 June 2025 | By Thermo Fisher Scientific
This webinar will explore how lipid formulations in softgels can enhance drug absorption and bioavailability.
In this article, Dave Elder reviews the European Medicines Agency (EMA)’s updated reflection paper on the qualification of non-mutagenic impurities (NMIs), which outlines alternative approaches to animal testing.
The research provides insight into effective measurement of particle adhesion, potentially enhancing pharmaceutical powder processing.
Courtney Soulsby, Sector Development Director, Healthcare at the British Standards Institute, reveals how the industry can prepare for PFAS regulations now to get ahead of the curve.
The proposed approach demonstrates benefit for real-world application, establishing more robust, adaptive, and economical process systems, the research suggests.
26 March 2025 | By Thermo Fisher Scientific Pharma Services
This webinar explores oral drug product development and how to address critical challenges such as complex formulations and regulatory hurdles.
The research suggests that the innovative 3D printing method has “great” potential for personalised treatments of intestinal inflammatory diseases.
The paper highlights a new analytical method that provides potential for sustainable use of nanomaterials and unique benefits compared to other spectrofluorimetric techniques.
The breakthrough promises to transform pharmaceutical manufacturing by enabling chemical reactions in water, reducing reliance on hazardous organic solvents.
Findings from the interim clinical study showed that the gel formulation enhanced quality of life in over half of cancer patients.
In this article, Dr Stephen Harrington, Director of Cell and Hydrogel Formulation and Francis Karanu, Vice President of Cell Therapy R&D, Likarda, discuss the benefits of hydrogel encapsulation in drug delivery and enhancing the bioavailability and functionality of cell therapies.
As a novel formulation, the “groundbreaking drug” is expected to improve the quality of life for young cancer patients with hearing loss.
